299 related articles for article (PubMed ID: 23490422)
1. Trials in type 1 diabetes: Antigen-specific therapies.
Coppieters KT; Harrison LC; von Herrath MG
Clin Immunol; 2013 Dec; 149(3):345-55. PubMed ID: 23490422
[TBL] [Abstract][Full Text] [Related]
2. Prevention versus intervention of type 1 diabetes.
Brooks-Worrell B; Palmer JP
Clin Immunol; 2013 Dec; 149(3):332-8. PubMed ID: 23803322
[TBL] [Abstract][Full Text] [Related]
3. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy trials for type 1 diabetes: the contribution of George Eisenbarth.
Skyler JS; Pugliese A
Diabetes Technol Ther; 2013 Jun; 15 Suppl 2(Suppl 2):S2-13-S2-20. PubMed ID: 23786294
[TBL] [Abstract][Full Text] [Related]
5. Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes.
Pozzilli P; Guglielmi C; Maggi D; Carlone A; Buzzetti R; Manfrini S
Curr Pharm Des; 2011; 17(29):3224-8. PubMed ID: 21864261
[TBL] [Abstract][Full Text] [Related]
6. Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of beta cell mass.
Waldron-Lynch F; von Herrath M; Herold KC
Novartis Found Symp; 2008; 292():146-55; discussion 155-8, 202-3. PubMed ID: 19203097
[TBL] [Abstract][Full Text] [Related]
7. [One step towards restoration of self-tolerance in human autoimmune diseases].
Chatenoud L
Med Sci (Paris); 2007 Feb; 23(2):167-71. PubMed ID: 17291426
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulators: Cell savers.
DeWeerdt S
Nature; 2012 May; 485(7398):S4-5. PubMed ID: 22616095
[No Abstract] [Full Text] [Related]
9. Immune therapy and β-cell death in type 1 diabetes.
Lebastchi J; Deng S; Lebastchi AH; Beshar I; Gitelman S; Willi S; Gottlieb P; Akirav EM; Bluestone JA; Herold KC
Diabetes; 2013 May; 62(5):1676-80. PubMed ID: 23423576
[TBL] [Abstract][Full Text] [Related]
10. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes.
Wang B; Tisch R
Immunol Res; 2008; 42(1-3):246-58. PubMed ID: 19052699
[TBL] [Abstract][Full Text] [Related]
11. How apoptotic β-cells direct immune response to tolerance or to autoimmune diabetes: a review.
Vives-Pi M; Rodríguez-Fernández S; Pujol-Autonell I
Apoptosis; 2015 Mar; 20(3):263-72. PubMed ID: 25604067
[TBL] [Abstract][Full Text] [Related]
12. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives.
Mallone R; Brezar V; Boitard C
Clin Dev Immunol; 2011; 2011():513210. PubMed ID: 21785617
[TBL] [Abstract][Full Text] [Related]
13. DiaPep277 peptide therapy in the context of other immune intervention trials in type 1 diabetes.
Tuccinardi D; Fioriti E; Manfrini S; D'Amico E; Pozzilli P
Expert Opin Biol Ther; 2011 Sep; 11(9):1233-40. PubMed ID: 21751937
[TBL] [Abstract][Full Text] [Related]
14. Clinical potential of antigen-specific therapies in type 1 diabetes.
Coppieters KT; Sehested Hansen B; von Herrath MG
Rev Diabet Stud; 2012; 9(4):328-37. PubMed ID: 23804270
[TBL] [Abstract][Full Text] [Related]
15. Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.
Bisikirska BC; Herold KC
Ann N Y Acad Sci; 2004 Dec; 1037():1-9. PubMed ID: 15699486
[TBL] [Abstract][Full Text] [Related]
16. Targeting the trimolecular complex.
Michels AW
Clin Immunol; 2013 Dec; 149(3):339-44. PubMed ID: 23537861
[TBL] [Abstract][Full Text] [Related]
17. Autoantigen-specific memory CD4+ T cells are prevalent early in progression to Type 1 diabetes.
Oling V; Reijonen H; Simell O; Knip M; Ilonen J
Cell Immunol; 2012; 273(2):133-9. PubMed ID: 22270037
[TBL] [Abstract][Full Text] [Related]
18. DiaPep277® and immune intervention for treatment of type 1 diabetes.
Schloot NC; Cohen IR
Clin Immunol; 2013 Dec; 149(3):307-16. PubMed ID: 24090708
[TBL] [Abstract][Full Text] [Related]
19. Reversal of New Onset Type 1 Diabetes by Oral
Mbongue JC; Rawson J; Garcia PA; Gonzalez N; Cobb J; Kandeel F; Ferreri K; Husseiny MI
Front Immunol; 2019; 10():320. PubMed ID: 30863412
[TBL] [Abstract][Full Text] [Related]
20. Combining MK626, a novel DPP-4 inhibitor, and low-dose monoclonal CD3 antibody for stable remission of new-onset diabetes in mice.
Ding L; Gysemans CA; Stangé G; Heremans Y; Yuchi Y; Takiishi T; Korf H; Chintinne M; Carr RD; Heimberg H; Pipeleers D; Mathieu C
PLoS One; 2014; 9(9):e107935. PubMed ID: 25268801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
